| Patients (n = 132) |
---|---|
Age, years | 58 [47–63] |
Male sex | 87 (65.9) |
Race | |
 Black | 33 (25.0) |
 White | 95 (72.0) |
 Other | 4 (3.0) |
Hematologic diagnosis | |
 Multiple myeloma | 32 (24.2) |
 Myelodysplastic syndrome | 9 (6.8) |
 Myelofibrosis | 9 (6.8) |
 Acute myeloid leukemia | 27 (20.5) |
 Acute lymphatic leukemia | 11 (8.3) |
 Chronic myeloid leukemia | 3 (2.3) |
 Chronic lymphatic leukemia | 2 (1.5) |
 Hodgkin’s lymphoma | 8 (6.1) |
 Non-Hodgkin’s lymphoma | 20 (15.2) |
 Aplastic anemia | 4 (3.0) |
 Other | 7 (5.4) |
Donor status | |
 Related | 28 (21.2) |
 Unrelated | 55 (41.7) |
 Not applicable | 49 (37.1) |
HCT type | |
 Autologous | 49 (37.1) |
 Allogenic | 83 (62.9) |
Cardiovascular diseases and risk factors | |
 Hypertension | 71 (53.8) |
 Smoking | 3 (2.3) |
 Diabetes mellitus | 20 (15.2) |
 Hypercholesterolemia | 35 (26.5) |
 Chronic kidney disease | 4 (3.0) |
 CAD | 14 (10.3) |
 Heart failure | 28 (21.2) |
 Atrial fibrillation | 33 (25.0) |
 Pericarditis | 6 (4.5) |
 None | 25 (18.9) |
Anti-hypertensive drugs prior to HCT | |
 b-blockers | 68 (51.5) |
 Calcium-channel blockers | 29 (22.0) |
 ACE inhibitors | 16 (12.1) |
 ARBs | 6 (4.5) |
 Furosemide/Torsemide | 21 (15.9) |
 Spironolactone | 8 (6.1) |
 None | 92 (69.7) |
Orthostatic Intolerance Syndromes | 47 (34.6) |
 Orthostatic hypotension pre-HCT | 3 (2.3) |
 Orthostatic hypotension post-HCT | 30 (22.7) |
 Tachycardia syndrome | 12 (9.1) |